AI CAPITAL INTELLIGENCE
Lifeforce Capital | Institution profile
Institution at a glance
Lifeforce Capital invests in care-delivery innovation and technology-led biotechnology. The firm says its portfolio companies use new technologies and care models to advance care delivery, alongside software-first techbio platforms. Its portfolio page lists Enveda. Enveda named Lifeforce Capital as an existing investor in its 2026 Series E; the individual investment amount was not disclosed.
Source verification date: · The investment themes and portfolio example are from Lifeforce Capital’s official website. Enveda’s company announcement identifies Lifeforce as an existing investor, corroborated by the financing report. The website does not publish comparable fund returns or an individual check size for this round.
Recorded financing connections
- Enveda2026-09-23 · Series E · USD 311,000,000
These are recorded participations, not a complete portfolio or performance score.
Names follow their disclosed form. Descriptive English renderings of Chinese names are not verified legal names. Original quotations are shown in their source language.
Key facts
| Published investment themes | Care delivery、New care models、Software-first techbio platforms |
|---|---|
| Company-described approach | Uses new technologies and care models to advance care delivery and support software-first techbio platforms. |
| Portfolio company shown on the firm’s website | Enveda |
Public record
- Lifeforce Capital’s portfolio page lists Enveda. Enveda’s September 23, 2026 announcement named Lifeforce as an existing investor in the $311 million Series E; its individual contribution was not disclosed.
- The financing database also records Lifeforce Capital as a participant in the round; the underlying report does not disclose an individual check size.
Official contact details
- Lifeforce Capital official website: Lifeforce Capital
Sources
- 1. Lifeforce Capital — Care Delivery and techbio investment themes
Our companies advance care delivery through new technologies and care models, and drive a paradigm shift away from traditional biotechnology with software-first techbio platforms.
- 2. Lifeforce Capital — portfolio page
Image: Enveda.png
- 3. Enveda — $311 million Series E announcement
Existing investors Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital also participated.
- 4. Enveda Series E financing report — BioXconomy
Existing investors Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital also participated.